Comment on: "Relative Effectiveness and Safety of the GLP-1 Receptor Agonists, Semaglutide and Liraglutide in the Treatment of Obese Type 2 Diabetics" [Letter].

IF 3 3区医学 Q3 ENDOCRINOLOGY & METABOLISM

Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy Pub Date : 2025-09-02 eCollection Date: 2025-01-01 DOI:10.2147/DMSO.S560523

Huina Zhu, Haoyue Jin, Binru Wang

引用次数: 0

查看原文本刊更多论文

评论：“GLP-1受体激动剂、西马鲁肽和利拉鲁肽治疗肥胖2型糖尿病的相对有效性和安全性”[Letter]。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy Pharmacology, Toxicology and Pharmaceutics-Pharmacology

CiteScore

5.90

自引率

6.10%

发文量

431

审稿时长

16 weeks

期刊介绍： An international, peer-reviewed, open access, online journal. The journal is committed to the rapid publication of the latest laboratory and clinical findings in the fields of diabetes, metabolic syndrome and obesity research. Original research, review, case reports, hypothesis formation, expert opinion and commentaries are all considered for publication.